Immunitybio Inc (IBRX)

Dec 20, 2024

D. Boral Capital Reiterates "Buy" Rating for ImmunityBio (NASDAQ:IBRX) - MarketBeat

Dec 20, 2024

Dec 19, 2024

ImmunityBio (NASDAQ:IBRX) Sets New 1-Year LowShould You Sell? - MarketBeat

Dec 19, 2024

Dec 17, 2024

ImmunityBio (NASDAQ:IBRX) Stock Price Down 5.6%Here's Why - MarketBeat

Dec 17, 2024

Dec 16, 2024

ImmunityBio: Forging A New Plan After Recent $100 Million Offering - Seeking Alpha

Dec 16, 2024

Dec 15, 2024

ImmunityBio Shares Plunge After Share Offering - Los Angeles Business Journal

Dec 15, 2024

Dec 14, 2024

ImmunityBio (NASDAQ:IBRX) Hits New 52-Week LowShould You Sell? - MarketBeat

Dec 14, 2024

Dec 13, 2024

ImmunityBio: Despite Share Price & Funding Woes Muddy Path To Long-Term Success (IBRX) - Seeking Alpha

Dec 13, 2024

Dec 12, 2024

ImmunityBio stock plummets on announcing common stock offering - MSN

Dec 12, 2024

Dec 12, 2024

D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering - Yahoo Finance

Dec 12, 2024

Dec 12, 2024

Form 424B5 ImmunityBio, Inc. - StreetInsider.com

Dec 12, 2024

Dec 12, 2024

SEC Form 424B5 filed by ImmunityBio Inc. - Quantisnow

Dec 12, 2024

Dec 11, 2024

ImmunityBio announces proposed public offering of common stock - MSN

Dec 11, 2024

Dec 11, 2024

ImmunityBio’s Cash Burn And Dilution Dampen Anktiva’s Potential (NASDAQ:IBRX) - Seeking Alpha

Dec 11, 2024

Dec 11, 2024

ImmunityBio Shares Slide 33% After Public Offering Prices - MarketWatch

Dec 11, 2024

Dec 11, 2024

What's Going On With ImmunityBio Shares Wednesday? - Benzinga

Dec 11, 2024

Dec 11, 2024

IMMUNITYBIO INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ImmunityBio, Inc.IBRX - The Eastern Progress Online

Dec 11, 2024

Dec 11, 2024

ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock - Business Wire

Dec 11, 2024

Dec 11, 2024

ImmunityBio Shares Down on Plans for Public Offering - MarketWatch

Dec 11, 2024

Dec 11, 2024

ImmunityBio plans public stock offering By Investing.com - Investing.com Canada

Dec 11, 2024

Dec 10, 2024

ImmunityBio plans public stock offering - Investing.com India

Dec 10, 2024

Dec 10, 2024

ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock - Business Wire

Dec 10, 2024

Dec 07, 2024

Biotech Billionaire Soon-Shiong Sued Over ImmunityBio Stock Move - MSN

Dec 07, 2024

Dec 07, 2024

More layoffs for ImmunityBio's Dunkirk facility - MSN

Dec 07, 2024

Dec 07, 2024

ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment - The Eastern Progress Online

Dec 07, 2024

Nov 30, 2024

(IBRX) Investment Analysis - Stock Traders Daily

Nov 30, 2024

Nov 25, 2024

ImmunityBio's (IBRX) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat

Nov 25, 2024

Nov 23, 2024

Immunitybio Inc. (IBRX): Among the Most Promising Cancer Stocks According to Hedge Funds - Insider Monkey

Nov 23, 2024

Nov 22, 2024

ImmunityBio and nCartes partner to automate clinical trial data processes - Clinical Trials Arena

Nov 22, 2024

Nov 22, 2024

Town hopeful after ImmunityBio tour - Evening Observer

Nov 22, 2024

Nov 22, 2024

Town Hopeful After ImmunityBio Tour - Jamestown Post Journal

Nov 22, 2024

Nov 21, 2024

ImmunityBio partners with nCartes to streamline trials - Investing.com

Nov 21, 2024

Nov 21, 2024

ImmunityBio and nCartes Enter Collaboration Agreement on Clinica - GuruFocus.com

Nov 21, 2024

Nov 21, 2024

ImmunityBio, nCartes announce collaboration on clinical trial data fulfillment - TipRanks

Nov 21, 2024

Nov 21, 2024

ImmunityBio partners with nCartes to streamline trials By Investing.com - Investing.com UK

Nov 21, 2024

Nov 21, 2024

ImmunityBio Partners with nCartes to Revolutionize Clinical Trial Data Management | IBRX Stock News - StockTitan

Nov 21, 2024

Nov 20, 2024

Wall Street Analysts Think ImmunityBio (IBRX) Could Surge 184.43%: Read This Before Placing a Bet - MSN

Nov 20, 2024

Nov 20, 2024

Immunitybio Inc earnings beat by $0.04, revenue topped estimates - Investing.com Nigeria

Nov 20, 2024

Nov 20, 2024

ImmunityBio (IBRX) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 20, 2024

Nov 19, 2024

ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months - BioSpace

Nov 19, 2024

Nov 19, 2024

ImmunityBio announces new data from QUILT 3.032 study - TipRanks

Nov 19, 2024

Nov 19, 2024

ImmunityBio's Bladder Cancer Drug Shows 71% Response Rate in Key Trial | IBRX Stock News - StockTitan

Nov 19, 2024

Nov 14, 2024

Following recent decline, ImmunityBio, Inc.'s (NASDAQ:IBRX) top shareholder Chief Scientific Officer Patrick Soon-Shiong sees holdings value drop by 11% - Simply Wall St

Nov 14, 2024

Nov 13, 2024

ImmunityBio Inc. Reports Earnings Amid Financial Challenges - TipRanks

Nov 13, 2024

Nov 13, 2024

ImmunityBio Inc (IBRX) Q3 2024 Earnings: GAAP EPS of -$0.12, Rev - GuruFocus.com

Nov 13, 2024

Nov 12, 2024

ImmunityBio: Q3 Earnings Snapshot - The Pioneer

Nov 12, 2024

Nov 12, 2024

ImmunityBio Inc. (IBRX) Quarterly 10-Q Report - Quartzy

Nov 12, 2024

Nov 12, 2024

Innovative Bladder Cancer Therapy Produces $6 Million in Sales - Precision Vaccinations

Nov 12, 2024

Nov 12, 2024

ImmunityBio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 12, 2024